<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0705245253
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        EVISTA 60 MG F-C TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RALOXIFENE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        88.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LILLY DEL CARIBE, INC." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LILLY DEL CARIBE, INC.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Eli Lilly Nederland B.V 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G03XC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Evista contains the active substance raloxifene hydrochloride.</p><p>Evista is used to treat and prevent osteoporosis in postmenopausal women. Evista reduces the risk of vertebral fractures in women with postmenopausal osteoporosis. A reduction in the risk of hip fractures has not been shown.</p><p>How Evista works</p><p>Evista belongs to a group of non-hormonal medicines called Selective Oestrogen Receptor Modulators (SERMs). When a woman reaches the menopause, the level of the female sex hormone oestrogen goes down. Evista mimics some of the helpful effects of oestrogen after the menopause.</p><p>Osteoporosis is a disease that causes your bones to become thin and fragile - this disease is especially common in women after the menopause. Although it may have no symptoms at first, osteoporosis makes you more likely to break bones, especially in your spine, hips and wrists and may cause back pain, loss of height and a curved back.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Evista</strong><strong>: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are being treated or have been treated for blood clots in the legs (deep vein thrombosis), in the lungs (pulmonary embolism) or in the eyes (retinal vein thrombosis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic (hypersensitive) to raloxifene or any of the other ingredients of this medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If there is still a possibility that you can get pregnant, EVISTA could harm your unborn child.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have liver disease (examples of liver disease include cirrhosis, mild hepatic impairment or cholestatic jaundice).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe kidney problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have any unexplained vaginal bleeding. This must be investigated by your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have active uterine cancer, as there is insufficient experience of Evista use in women with this disease.</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before you take Evista.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are immobilised for some time such as being wheel-chair bound, needing to be admitted to a hospital or having to stay in bed while recovering from an operation or an unexpected illness as these may increase your risk of blood clots (deep vein thrombosis, pulmonary embolism or retinal vein thrombosis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have had a cerebrovascular accident (e.g. stroke), or if your doctor has told you that you are at high risk of having one.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have liver disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are suffering from breast cancer, as there is insufficient experience of Evista use in women with this disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are receiving oral oestrogen therapy.</p><p>It is unlikely that Evista will cause vaginal bleeding. So any vaginal bleeding while you take Evista is unexpected. You should have this investigated by your doctor.</p><p>Evista does not treat postmenopausal symptoms, such as hot flushes.</p><p>Evista lowers total cholesterol and LDL (&quot;bad&quot;) cholesterol. In general, it does not change triglycerides or HDL (&quot;good&quot;) cholesterol. However, if you have taken oestrogen in the past and had extreme elevations in triglycerides, you should talk to your doctor before taking Evista. &nbsp;</p><p><strong>Evista</strong><strong> contains lactose</strong></p><p>If you have been told by your doctor that you have an intolerance to lactose, a type of sugar, contact your doctor before taking this medicinal product.</p><p><strong>Other medicines and </strong><strong>Evista</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>If you are taking digitalis medicines for your heart or anticoagulants like warfarin to thin your blood, your doctor may need to adjust your dose of these medicines.</p><p>Tell your doctor if you are taking cholestyramine which is mainly used as lipid-lowering medicine, because Evista may not work as well.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Evista is for use only by postmenopausal women and must not be taken by women who could still have a baby. Evista could harm your unborn child.</p><p>Do not take Evista if you are breast-feeding as it might be excreted in mother&#39;s milk.</p><p><strong>Driving and using machines</strong></p><p>Evista has no or negligible effects on driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>The dose is one tablet a day. It does not matter what time of day you take your tablet but taking the tablet at the same time each day will help you remember to take it. You may take it with or without food.</p><p>The tablets are for oral use.</p><p>Swallow the tablet whole. If you wish you may take a glass of water with it. Do not break or crush the tablet before taking it. A broken or crushed tablet may taste bad and there is a possibility that you will receive an incorrect dose.</p><p>Your doctor will tell you how long you should continue to take Evista. The doctor may also advise you to take calcium and vitamin D supplements.</p><p><strong>If you take more Evista than you should</strong></p><p>Tell your doctor or pharmacist. If you take more EVISTA than you should you could have leg cramps and dizziness.</p><p><strong>If you forget to take</strong> <strong>Evista</strong></p><p>Take a tablet as soon as you remember and then continue as before. Do not take a double dose to make up for a forgotten tablet dose.</p><p><strong>If you stop taking Evista</strong><strong> </strong></p><p>You should talk to your doctor first.</p><p>It is important that you continue taking Evista for as long as your doctor prescribes the medicine, Evista can treat or prevent your osteoporosis only if you continue to take the tablets.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects although not everybody gets them. The majority of side effects seen with Evista have been mild.</p><p>The most common side effects (affects more than 1 user in 10) are:</p><p>&middot;&nbsp;&nbsp; Hot flushes (vasodilatation)</p><p>&middot;&nbsp;&nbsp; Flu syndrome</p><p>&middot;&nbsp;&nbsp; Gastrointestinal symptoms such as nausea, vomiting, abdominal pain and stomach upset</p><p>&middot;&nbsp;&nbsp; Increased blood pressure</p><p>Common side effects (affects 1 to 10 users in 100) are:</p><p>&middot;&nbsp;&nbsp; Headache including migraine</p><p>&middot;&nbsp;&nbsp; Leg cramps</p><p>&middot;&nbsp;&nbsp; Swelling of hands, feet and legs (peripheral oedema)</p><p>&middot;&nbsp;&nbsp; Gallstones</p><p>&middot;&nbsp;&nbsp; Rash</p><p>&middot;&nbsp;&nbsp; Mild breast symptoms such as pain, enlargement and tenderness</p><p>Uncommon side effects (affects 1 to 10 users in 1000) are:</p><p>&middot;&nbsp;&nbsp; Increased risk of blood clots in the legs (deep vein thrombosis)</p><p>&middot;&nbsp;&nbsp; Increased risk of blood clots in the lungs (pulmonary embolism)</p><p>&middot;&nbsp;&nbsp; Increased risk of blood clots in the eyes (retinal vein thrombosis)</p><p>&middot;&nbsp;&nbsp; Skin around the vein is red and painful (superficial vein thrombophlebitis)</p><p>&middot;&nbsp;&nbsp; Blood clot in an artery (for example stroke, including an increased risk of dying from stroke)</p><p>&middot;&nbsp;&nbsp; Decrease in the number of the platelets in the blood</p><p>In rare cases, blood levels of liver enzymes may increase during treatment with Evista.</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in section 6. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use after the expiry date which is stated on the pack after EXP. The expiry date refers to the last day of the month.</p><p>Store in the original package. Do not freeze. Store below 30&deg;C.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is raloxifene hydrochloride. Each tablet contains 60&nbsp;mg of raloxifene hydrochloride, which is equivalent to 56&nbsp;mg raloxifene.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients&nbsp; are:</p><p>Tablet Core: Povidone, polysorbate 80,&nbsp; lactose, lactose monohydrate, crospovidone, magnesium stearate.</p><p>Tablet coating: Titanium dioxide (E 171), polysorbate 80, hypromellose, macrogol 400, carnauba wax.</p><p>Ink: Shellac, propylene glycol, indigo carmine (E 132).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Evista are white, oval, film coated tablets which are marked with the number 4165. They are packed in blisters or in plastic bottles. The blister boxes contain 14, 28 or 84 tablets. The bottles contain 100 tablets. Not all pack sizes may be marketed.
	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Eli Lilly Nederland B.V. Papendorpseweg 83, 3528 BJ Utrecht. The Netherlands.</p><p><strong>Manufacturer, Primary and Secondary Packaging Site</strong></p><p>Lilly S.A., Avda. de la Industria 30, 28108 Alcobendas (Madrid), Spain.</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Eli Lilly &amp; Company &ndash; Saudi Arabia</p><p>PO Box 92120</p><p>16th Floor, Building Number 3074,</p><p>Tower B, Olaya Towers</p><p>Prince Mohamed Ibn Abdulaziz Street</p><p>Olaya, Riyadh</p><p>Kingdom of Saudi Arabia</p><p>Direct Line:&nbsp; +966 11 461 7800, +966 11 4617898&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Fax: +966 11 217 9900</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in  June 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي إفيستا على المادة الفعالة رالوكسيفين هيدروكلوريد.</p><p>يستخدم إفيستا للعلاج والوقاية من هشاشة العظام لدى النساء في مرحلة ما بعد انقطاع الطمث. ويقلل إفيستا من خطر حدوث كسور الفقرات لدى النساء المصابات بهشاشة العظام ما بعد انقطاع الطمث. ولم يظهر انخفاض في خطر الإصابة بكسور في عظام الحوض.</p><p>كيفية عمل إفيستا</p><p>ينتمي إفيستا إلى مجموعة الأدوية غير الهرمونية المسماة &quot;المعدلات الانتقائية لمستقبلات الإستروجين&quot; (SERMs). عندما تبلغ المرأة مرحلة انقطاع الطمث، يقل مستوى هرمون الإستروجين الجنسي الأنثوي. يعمل عقار إفيستا على محاكاة بعض التأثيرات المفيدة للإستروجين بعد انقطاع الطمث.</p><p>هشاشة العظام هي مرض يجعل عظامك رقيقة وهشة ويشيع هذا المرض - بصفة خاصة - لدى النساء في مرحلة ما بعد انقطاع الطمث. وبرغم أن مرض هشاشة العظام قد لا يسبب أعراضاً في البداية، إلا أنه يجعلكِ أكثر عرضة للإصابة بكسور العظام، خاصة في الفقرات وعظام الحوض والرسغين وقد يسبب لك شعوراً بألم في الظهر وتناقص الطول وانحناء الظهر.&nbsp; &nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>امتنعي عن تناول إفيستا:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قيد العلاج أو سبق علاجك من جلطات الدم في الساقين (التخثر الوريدي العميق)، أو في الرئتين (التخثر الرئوي)، أو في العينين (التخثر الوريدي الشبكي).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ مصابة بالحساسية (فرط الحساسية) لمادة الرالوكسيفين أو أي من مكونات إفيستا الأخرى (المذكورة في الفقرة 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كانت احتمالية حدوث الحمل مازالت قائمة لديك، فإن إيفستا قد يضر بجنينك.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ مصابة بمرض كبدي (تشمل أمثلة الأمراض الكبدية تليف الكبد أو القصور الكبدي البسيط أو اليرقان الناتج عن ركود الصفراء).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين من مشكلات كلوية شديدة.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ مصابة بأي نزيف مهبلي لسبب غير واضح، فلابد من بحث الأمر من قبل طبيبك المعالج.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابة بورم سرطاني نشط بالرحم، إذ أن الخبرة المتعلقة باستخدام إفيستا لعلاج النساء المصابات بهذا المرض، ما تزال غير كافية.</p><p><strong>تحذيرات واحتياطات</strong></p><p>استشيري طبيبك المعالج قبل تناول الدواء إيفيستا.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تكوني قادرة على الحركة لفترة من الزمن كأن تكوني ملازمة لكرسي متحرك أو بحاجة للبقاء في المستشفى أو مضطرة لملازمة الفراش خلال فترة التعافي من عملية جراحية أو حالة مرضية غير متوقعة، حيث يزيد ما سبق من خطر تعرضك لجلطات دموية (التخثر الوريدي العميق، أو التخثر الرئوي، أو التخثر الوريدي الشبكي).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن سبقت إصابتك بحادث وعائي دماغي (كالسكتة الدماغية)، أو إذا أخبرك طبيبك المعالج أنك معرضة بدرجة كبيرة للإصابة بذلك.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ مصابة بمرض كبدي</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعانين من سرطان الثدي، إذ أن الخبرة المتعلقة باستخدام إفيستا لعلاج النساء المصابات بهذا المرض، ما تزال غير كافية.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناولين علاج الإستروجين الفموي.</p><p>&nbsp;</p><p>من غير المُرجح أن يتسبب إفيستا في حدوث نزيف مهبلي. لذلك من غير المتوقع إصابتك بنزيف مهبلي عند أخذك إيفيستا ، فلابد من بحث الأمر من قبل طبيبك المعالج.</p><p>لا يفيد إفيستا في علاج أعراض ما بعد انقطاع الطمث، مثل الهبّات الساخنة.</p><p>يخفض إفيستا من مستوى كل من إجمالي الكوليسترول وكوليسترول البروتين الدهني منخفض الكثافة (&quot;الضار&quot;). وبصفة عامة، فإنه لا يغير من مستويات أي من الدهون الثلاثية أو كوليستيرول البروتين الدهني مرتفع الكثافة (&quot;النافع&quot;). ومع ذلك، إذا كنت قد تناولت الإستروجين سابقًا وحدثت لك ارتفاعات شديدة في مستويات الدهون الثلاثية، فينبغي لك استشارة طبيبك المعالج قبل الإقدام على تناول إفيستا .</p><p><strong>يحتوي إيفيستا على اللاكتوز </strong></p><p>إذا سبق وأخبرك الطبيب أنك مصاب بعدم تحمّل اللاكتوز، وهو أحد أنواع السكر، فاتصل بطبيبك قبل تناولك لهذا المنتج الدوائي.</p><p><strong>&nbsp;الأدوية الأخرى وإيفيستا</strong></p><p>يرجى إبلاغ طبيبك المعالج أو الصيدلي إذا كنت تتناولين حالياً أو تناولت مؤخراً أو يمكن أن تتناولي أية أدوية أخرى، بما في ذلك الأدوية التي يتم صرفها بدون وصفة طبية.</p><p>إذا كنت تتناولين أدوية ديجيتاليس للقلب أو تتناولين أياً من مضادات التخثر مثل عقار وارفارين لزيادة سيولة الدم لديك، فقد يحتاج طبيبك المعالج لتعديل الجرعة التي تتناولينها من هذه الأدوية.</p><p>أخبري طبيبك إذا كنت تتناولين كوليستيرامين والذي يستخدم أساسًا كعقار خافض للدهون، وذلك لأن إيفيستا قد لا يكون فعالاً كذلك.</p><p><strong>الحمل والرضاعة الطبيعية</strong></p><p>يقتصر استخدام إفيستا على النساء في مرحلة ما بعد انقطاع الطمث، ويحظر نهائياً تناوله من قبل النساء اللواتي مازلن يتمتعن بفرصة على الإنجاب. فعقار إفيستا قد يؤذي جنينك.&nbsp; &nbsp;</p><p>لا تتناولي إفيستا إذا كنت مُرضعة إذ أنه قد يُفرَز في لبن الأم.</p><p><strong>القيادة واستخدام الآلات</strong></p><p>ليس لعقار إفيستا أية تأثيرات أو لديه آثار ضئيلة على قدرتك على القيادة وتشغيل الآلات.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احرصي دائماً على تناول هذا المنتج كما نصحك طبيبك المعالج بالضبط، وينبغي لك مراجعة طبيبك أو الصيدلي إذا ساورك شك.</p><p>الجرعة عبارة عن قرص واحد يوميًا. ولا يهم في أي وقت من اليوم تتناولين القرص إلا أن تناول القرص في نفس التوقيت كل يوم سوف يساعدك أن تتذكري تناوله. ويمكنك تناول القرص مع الطعام أو بدونه.</p><p>الأقراص معدة للتناول عن طريق الفم.</p><p>يجب ابتلاع القرص كاملاً. ويمكنك تناول كوب من الماء معه بحسب رغبتك. لا تكسر أو تهشم القرص قبل تناوله. قد يكون طعم القرص المكسور أو المهشم سيئًا، كما توجد احتمالية تلقيك لجرعة خاطئة.</p><p>سوف يخبرك طبيبك المعالج بمدة استمرارِك في تناول إفيستا. وقد ينصحك الطبيب أيضاً بتناول مكملات الكالسيوم وفيتامين (د).</p><p><strong>إذا تناولت جرعة زائدة من إفيستا </strong></p><p>بادري بإبلاغ طبيبك أو الصيدلي. إذا تناولت جرعة زائدة من إفيستا، فيمكن أن تتعرضي لتقلصات بالساق ودوخة.</p><p><strong>إذا نسيتِ تناول إفيستا </strong></p><p>بادري بتناول قرص بمجرد أن تتذكري ثم استمري على النحو السابق. لا تتناولي جرعة مضاعفة لتهويض جرعة القرص المنسي.</p><p><strong>إذا توقفت عن تناول إفيستا </strong></p><p>ينبغي لك استشارة طبيبك المعالج أولاً.</p><p>من المهم أن تستمري في تناول إفيستا للمدة التي يصفها طبيبك. يعالج إفيستا أويقيك من الإصابة بهشاشة العظام فقط في حالة استمرارك في تناول الأقراص</p><p>إذا كان لديكِ مزيد من الأسئلة بخصوص استخدام هذا الدواء، فاستشيري طبيبك المعالج أو الصيدلي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو شأن كافة الأدوية، فإن إفيستا يمكن أن يسبب آثاراً جانبية إلا أنها لا تصيب كل من يتناول الدواء. وقد كانت غالبية الآثار الجانبية التي لوحظ وقوعها مع استخدام إفيستا بسيطة.</p><p>تتمثل الآثار الجانبية الأكثر شيوعاً (تصيب أكثر من واحد من بين كل 10) في:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهبّات الساخنة (التوسّع الوعائي)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة الإنفلونزا</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض بالجهاز الهضمي كالغثيان، والقيء، وألم البطن، وتهيج المعدة</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم</p><p>تتمثل الآثار الجانبية الشائعة (تصيب ما يتراوح من 1 إلى 10 من بين كل 100) في:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع، بما في ذلك الصجاع النصفي</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلصات الساقين</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم اليدين والقدمين والساقين (وذمة طرفية)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحصوات المرارية</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض بسيطة في الثديين، كالألم والتضخم والألم المصاحب للّمس.</p><p>تتمثل الآثار الجانبية غير الشائعة (التي تصيب ما يتراوح من 1 إلى 10 من بين كل 1000) في:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة خطر حدوث جلطات دموية في الساقين (التخثر الوريدي العميق)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة خطر حدوث جلطات دموية في الرئتين (التخثر الرئوي)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة خطر حدوث جلطات دموية في العينين (التخثر الوريدي الشبكي)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد المحيط بالوريد مع الشعور بألم (التهاب وريدي تخثري بالأوردة السطحية)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطة دموية في أحد الشرايين (كالسكتة الدماغية، بما في ذلك زيادة خطر التعرض للوفاة نتيجة السكتة الدماغية)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض تعداد الصفائح الدموية</p><p>في حالات نادرة، قد ترتفع مستويات إنزيمات الكبد بالدم خلال فترة العلاج بعقار إفيستا .</p><p><strong>الإبلاغ عن لآثار الجانبية</strong></p><p>في حالة إصابتك بأية آثار جانبية، فاتصل بطبيبك أو الصيدلي، ويتضمن ذلك أية آثار جانبية لم ترد في هذه النشرة. یمکنك أیضا الإبلاغ عن الآثار الجانبیة مباشرة من خلال نظام الإبلاغ الوطني المدرج في القسم 6. من خلال الإبلاغ عن الآثار الجانبیة یمکنك المساعدة في توفیر المزید من المعلومات حول سلامة ھذا الدواء.&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يُحفظ هذا الدواء بعيداً عن نظر و متناول &nbsp;الأطفال.</p><p>يُحظر استخدام الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة بعدEXP . يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p>يُخزن في العبوة الأصلية، ولا يُجمّد. يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p>يحظر التخلص من الأدوية عن طريق مياه الصرف الصحي أو مع النفايات المنزلية. اسألي الصيدلي الذي تتعاملين معه عن كيفية التخلص من الأدوية التي لم تعودي بحاجة إليها. سوف تساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي رالوكسيفين هيدروكلوريد. ويحتوي كل قرص على 60 ملجم من رالوكسيفين هيدروكلوريد، وهو ما يعادل 56 ملجم من رالوكسيفين.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وتتضمن باقي المكونات:</p><p>لًب القرص: بوفيدون، وبوليسوربات 80، ولاكتوز، ولاكتوز أحادي التموه، وكروسبوفيدون، وستيارات الماغنسيوم.</p><p>غلاف القرص: ثاني أكسيد التيتانيوم (إي 171)، وبوليسوربات 80، وهيبروميللوز، وماكروجول 400، وشمع كارنوبا.</p><p>مداد (حِبر): شيلاك، وبروبيلين جليكول، ومكسب لون قرمزي نيلي (إي 132).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص إفيستا عبارة عن أقراص بيضاء اللون بيضاوية الشكل مغلفة بطبقة رقيقة مدموغة بالرقم 4165. وهي معبأة في شرائط او في زجاجات بلاستيكية. يحتوي الشريط على 14 أو 28 أو 84 قرصًا. تحتوي الزجاجة على 100 قرص. قد لا تكون جميع أحجام العبوات مطروحة في السوق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>صاحب رخصة التسويق</strong></p><p>إيلاي ليلي جادة ندرلاند بابندوربسوغ 83، 3528، &nbsp;BJأوتركت، هولندا.</p><p><strong>الشركة المصنّعة و موقع التغليف الأولي و الثانوي</strong></p><p>ليلي س.أ. جادة اندستريا 30، 28108 ألكوبنداس، مدريد، إسبانيا.</p><p><strong>&nbsp;</strong>للحصول على معلومات عن هذا الدواء، يُرجى الاتصال بالشركة صاحبة تفويض التسويق المحلي:</p><p>شركة إيلاي ليلي آند كومباني- المملكة العربية السعودية</p><p>ص.ب92120 :</p><p>الطابق16 ، مبنى رقم 3074</p><p>برج ب، أبراج العُليَّا</p><p>شارع الأمير محمد بن عبد العزيز</p><p>العُليَّا، الرياض</p><p>المملكة العربية السعودية</p><p>الخط المباشر&nbsp; 966114617898+, 966114617800+&nbsp;&nbsp;</p><p>الفاكس:&nbsp; 966112179900+</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            كان آخر تصديق على هذه النشرة في يونيو 2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Evista 60 mg film coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film coated tablet contains 60 mg raloxifene hydrochloride, equivalent to 56 mg raloxifene free base.
Excipient with known effect: 
Each tablet contains lactose (149.40 mg).
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablet.
Elliptically shaped, white tablets imprinted with the code ’4165’.



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Evista is indicated for the treatment and prevention of osteoporosis in postmenopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated.</p><p>When determining the choice of Evista or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The recommended dose is one tablet daily by oral administration, which may be taken at any time of the day without regard to meals. Due to the nature of this disease process, Evista is intended for long term use.</p><p>Generally calcium and vitamin D supplements are advised in women with a low dietary intake.</p><p><em>Elderly:</em></p><p>No dose adjustment is necessary for the elderly.</p><p><em>Renal impairment: </em></p><p>Evista should not be used in patients with severe renal impairment (see section 4.3). In patients with moderate and mild renal impairment, Evista should be used with caution.</p><p><em>Hepatic impairment: </em></p><p>Evista should not be used in patients with hepatic impairment (see section 4.3 and 4.4).</p><p><em>Paediatric population:</em></p><p>Evista should not be used in children of any age. There is no relevant use of Evista in the paediatric population.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Must not be used in women with child bearing potential (see section 4.6). 

Active or past history of venous thromboembolic events (VTE), including deep vein thrombosis, pulmonary embolism and retinal vein thrombosis.

Hepatic impairment including cholestasis.

Severe renal impairment. 

Unexplained uterine bleeding.

Evista should not be used in patients with signs or symptoms of endometrial cancer as safety in this patient group has not been adequately studied.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Raloxifene is associated with an increased risk for venous thromboembolic events that is similar to the reported risk associated with current use of hormone replacement therapy. The risk-benefit balance should be considered in patients at risk of venous thromboembolic events of any aetiology. Evista</p><p>should be discontinued in the event of an illness or a condition leading to a prolonged period of immobilisation. Discontinuation should happen as soon as possible in case of the illness, or from 3 days before the immobilisation occurs. Therapy should not be restarted until the initiating condition has resolved and the patient is fully mobile.</p><p>In a study of postmenopausal women with documented coronary heart disease or at increased risk for coronary events, raloxifene did not affect the incidence of myocardial infarction, hospitalized acute coronary syndrome, overall mortality, including overall cardiovascular mortality, or stroke, compared to placebo. However, there was an increase in death due to stroke in women assigned to raloxifene. The incidence of stroke mortality was 2.2 per 1000 women per year for raloxifene versus 1.5 per 1000 women per year for placebo (see section 4.8). This finding should be considered when prescribing raloxifene for<strong><em> </em></strong>postmenopausal women with a history of stroke or other significant stroke risk factors, such as transient ischemic attack or atrial fibrillation.</p><p>There is no evidence of endometrial proliferation. Any uterine bleeding during Evista therapy is unexpected and should be fully investigated by a specialist. The two most frequent diagnoses associated with uterine bleeding during raloxifene treatment were endometrial atrophy and benign endometrial polyps. In postmenopausal women who received raloxifene treatment for 4 years, benign endometrial polyps were reported in 0.9 % compared to 0.3 % in women who received placebo treatment.</p><p>Raloxifene is metabolised primarily in the liver. Single doses of raloxifene given to patients with cirrhosis and mild hepatic impairment (Child-Pugh class A) produced plasma concentrations of raloxifene which were approximately 2.5 times the controls. The increase correlated with total bilirubin concentrations. Therefore Evista is not recommended to be used in patients with hepatic insufficiency. Serum total bilirubin, gamma-glutamyl transferase, alkaline phosphatase, ALT and AST should be closely monitored during treatment if elevated values are observed.</p><p>Limited clinical data suggest that in patients with a history of oral oestrogen-induced hypertriglyceridemia (&gt;5.6 mmol/l), raloxifene may be associated with a marked increase in serum triglycerides. Patients with this medical history should have serum triglycerides monitored when taking raloxifene.</p><p>The safety of Evista in patients with breast cancer has not been adequately studied. No data are available on the concomitant use of Evista and agents used in the treatment of early or advanced breast cancer. Therefore, Evista should be used for osteoporosis treatment and prevention only after the treatment of breast cancer, including adjuvant therapy, has been completed.</p><p>As safety information regarding co-administration of raloxifene with systemic oestrogens is limited, such use is not recommended.</p><p>Evista<strong><em> is not effective in reducing vasodilatation (hot flushes), or other symptoms of the menopause</em></strong> associated with oestrogen deficiency.</p><p>Evista contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concurrent administration of either calcium carbonate or aluminium and magnesium-hydroxide containing antacids do not affect the systemic exposure of raloxifene.</p><p>Co-administration of raloxifene and warfarin does not alter the pharmacokinetics of either compound. However, modest decreases in the prothrombin time have been observed, and if raloxifene is given concurrently with warfarin or other coumarin derivatives, the prothrombin time should be monitored. Effects on prothrombin time may develop over several weeks if Evista treatment is started in patients who are already on coumarin anticoagulant therapy.</p><p>Raloxifene has no effect on the pharmacokinetics of methylprednisolone given as a single dose.</p><p>Raloxifene does not affect the steady-state AUC of digoxin. The C<sub>max</sub> of digoxin increased by less than 5 %.</p><p>The influence of concomitant medication on raloxifene plasma concentrations was evaluated in the prevention and treatment trials. Frequently co-administered medicinal products included: paracetamol, non<strong>-</strong>steroidal anti-inflammatory drugs (such as acetylsalicylic acid, ibuprofen, and naproxen), oral antibiotics, H1 antagonists, H2 antagonists, and benzodiazepines. No clinically relevant effects of the co-administration of the agents on raloxifene plasma concentrations were identified.</p><p>Concomitant use of vaginal oestrogen preparations was allowed in the clinical trial programme, if necessary to treat atrophic vaginal symptoms. Compared to placebo there was no increased use in Evista treated patients.</p><p><em>In vitro,</em> raloxifene did not interact with the binding of warfarin, phenytoin, or tamoxifen.</p><p>Raloxifene should not be co-administered with cholestyramine (or other anion exchange resins), which significantly reduces the absorption and enterohepatic cycling of raloxifene.</p><p>Peak concentrations of raloxifene are reduced with co-administration with ampicillin. However, since the overall extent of absorption and the elimination rate of raloxifene are not affected, raloxifene can be concurrently administered with ampicillin.</p><p>Raloxifene modestly increases hormone-binding globulin concentrations, including sex steroid binding globulins (SHBG), thyroxine binding globulin (TBG), and corticosteroid binding globulin (CBG), with corresponding increases in total hormone concentrations. These changes do not affect concentrations of free hormones.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Evista is only for use in postmenopausal women.</p><p>Evista must not be taken by women of child bearing potential. Raloxifene may cause foetal harm when administered to a pregnant woman. If this medicinal product is used mistakenly during pregnancy or the patient becomes pregnant while taking it, the patient should be informed of the potential hazard to the foetus (see section 5.3).</p><p><u>Breast-feeding</u></p><p>It is unknown whether raloxifene/raloxifene metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. Its clinical use, therefore, cannot be recommended in breast-feeding women. Evista may affect the development of the baby.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Raloxifene has no or negligible influence on the ability to drive and use machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>a. Summary of the safety profile</em></p><p>The clinically most important adverse reactions reported in postmenopausal women treated with Evista were venous thromboembolic events (see section 4.4), which occurred in less than 1% of treated patients.</p><p><em>b. Tabulated summary of adverse reactions</em></p><p>The table below gives the adverse reactions and frequencies observed in treatment and prevention studies involving over 13,000 postmenopausal women along with adverse reactions arising from postmarketing reports. The duration of treatment in these studies ranged from 6 to 60 months. The majority of adverse reactions have not usually required cessation of therapy.</p><p>The frequencies for postmarketing reports were calculated from placebo-controlled clinical trials (comprising a total of 15,234 patients, 7,601 on raloxifene 60 mg and 7,633 on placebo) in postmenopausal women with osteoporosis, or established coronary heart disease (CHD) or increased risk for CHD, without comparison to the frequencies of adverse events in the placebo assignment groups.</p><p>In the prevention population discontinuations of therapy due to any adverse reaction occurred in 10.7&nbsp;% of 581 Evista treated patients and 11.1&nbsp;% of 584 placebo-treated patients. In the treatment population discontinuations of therapy due to any clinical adverse event occurred in 12.8&nbsp;% of 2,557 Evista treated patients and 11.1&nbsp;% of 2,576 placebo treated patients.</p><p>The following convention has been used for the classification of the adverse reactions: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong><br /><em>Uncommon:</em><strong> </strong>Thrombocytopenia <sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong><br /><em>Common<strong>: </strong></em>Headache, including migraine <sup>a</sup></p><p><em>Uncommon:</em> Fatal strokes</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p><p><em>Very common:</em> Vasodilation (hot flushes)</p><p><em>Uncommon: </em>Venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, retinal vein thrombosis, superficial vein thrombophlebitis,</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Arterial thromboembolic reactions <sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p><p><em>Very common</em>:<strong> </strong>Gastrointestinal symptoms <sup>a</sup> such as nausea, vomiting, abdominal pain, dyspepsia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p><p><em>Common</em>:<strong> </strong>Rash <sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p><p><em>Common:</em> Leg cramps</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p><p><em>Common:</em><strong> </strong>Mild breast symptoms <sup>a</sup> such as pain, enlargement and tenderness</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p><p><em>Very common:</em> Flu syndrome</p><p><em>Common:</em> Peripheral oedema</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong><br /><em>Very common:</em><strong> </strong>Increased blood pressure <sup>a</sup></p></td></tr></tbody></table><p><sup>a&nbsp; </sup>Term(s) included based on postmarketing experience.</p><p>&nbsp;</p><p><em>c. Description of selected adverse reactions</em></p><p>Compared with placebo-treated patients the occurrence of vasodilatation (hot flushes) was modestly increased in Evista patients (clinical trials for the prevention of osteoporosis, 2 to 8 years postmenopausal, 24.3 % Evista and 18.2&nbsp;% placebo; clinical trials for the treatment of osteoporosis, mean age 66, 10.6&nbsp;% for Evista and 7.1&nbsp;% placebo). This adverse reaction was most common in the first 6 months of treatment, and seldom occurred de novo after that time.</p><p>In a study of 10,101 postmenopausal women with documented coronary heart disease or at increased risk for coronary events (RUTH), the occurrence of vasodilatation (hot flushes) was 7.8 % in the raloxifene-treated patients and 4.7 % in the placebo-treated patients.</p><p>Across all placebo-controlled clinical trials of raloxifene in osteoporosis, venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis occurred at a frequency of approximately 0.8&nbsp;% or 3.22 cases per 1,000 patient years. A relative risk of 1.60 (CI 0.95, 2.71) was observed in Evista treated patients compared to placebo. The risk of a thromboembolic event was greatest in the first four months of therapy. Superficial vein thrombophlebitis occurred in a frequency of less than 1&nbsp;%.</p><p><u>In the RUTH study</u><em>,</em> venous thromboembolic events occurred at a frequency of approximately 2.0 % or 3.88&nbsp;cases per 1,000 patient‑years in the raloxifene group and 1.4 % or 2.70 cases per 1,000&nbsp;patient‑years in the placebo group. The hazard ratio for all VTE events in the RUTH study was HR = 1.44 (1.06 &ndash; 1.95). Superficial vein thrombophlebitis occurred in a frequency of 1 % in the raloxifene group and 0.6 % in the placebo group.</p><p>In the RUTH study, raloxifene did not affect the incidence of stroke, compared to placebo. However, there was an increase in death due to stroke in women assigned to raloxifene. The incidence of stroke mortality was 2.2 per 1,000 women per year for raloxifene versus 1.5 per 1,000 women per year for placebo (see section 4.4). During an average follow-up of 5.6 years, 59 (1.2%) raloxifene-treated women died due to a stroke compared to 39 (0.8%) placebo-treated women.</p><p>Another adverse reaction observed was leg cramps (5.5&nbsp;% for Evista, 1.9&nbsp;% for placebo in the prevention population and 9.2&nbsp;% for Evista, 6.0&nbsp;% for placebo in the treatment population).</p><p>In the RUTH study, leg cramps were observed in 12.1 % of raloxifene-treated patients and 8.3 % of placebo-treated patients.</p><p>Flu syndrome was reported by 16.2&nbsp;% of Evista treated patients and 14.0&nbsp;% of placebo treated patients.</p><p>One further change was seen which was not statistically significant (p&nbsp;&gt;&nbsp;0.05), but which did show a significant dose trend. This was peripheral oedema, which occurred in the prevention population at an &nbsp;incidence of 3.1 % for Evista and 1.9 % for placebo; and in the treatment population occurred at an incidence of 7.1 % for Evista and 6.1 % for placebo.</p><p>In the RUTH study, peripheral oedema occurred in 14.1 % of the raloxifene-treated patients and 11.7% of the placebo-treated patients, which was statistically significant.</p><p>Slightly decreased (6-10&nbsp;%) platelet counts have been reported during raloxifene treatment in placebo-controlled clinical trials of raloxifene in osteoporosis.</p><p>Rare cases of moderate increases in AST and/or ALT have been reported where a causal relationship to raloxifene can not be excluded. A similar frequency of increases was noted among placebo patients.</p><p>In a study (RUTH) of postmenopausal women with documented coronary heart disease or at increased risk for coronary events, an additional adverse reaction of cholelithiasis occurred in 3.3 % of patients treated with raloxifene and 2.6 % of patients treated with placebo. Cholecystectomy rates for raloxifene (2.3 %) were not statistically significantly different from placebo (2.0 %).</p><p>Evista (n&nbsp;=&nbsp;317) was compared with continuous combined (n&nbsp;=&nbsp;110) hormone replacement therapy (HRT) or cyclic (n&nbsp;=&nbsp;205) HRT patients in some clinical trials. The incidence of breast symptoms and uterine bleeding in raloxifene treated women was significantly lower than in women treated with either form of HRT.</p><p>Reporting of suspected adverse reactions</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed below.</p><table border="1" cellspacing="0" cellpadding="0" style="width:347px"><tbody><tr><td style="vertical-align:top; width:344px"><p><strong>To report any side effect(s):</strong></p><p>&nbsp;</p><p>The -National Pharmacovigilance Center (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o SFDA Call Center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa&nbsp;</p><p>o Website: https://ade.sfda.gov.sawww.sfda.gov.sa</p><p><strong>&nbsp;</strong></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In some clinical trials, daily doses were given up to 600&nbsp;mg for 8 weeks and 120&nbsp;mg, for 3 years. No cases of raloxifene overdose were reported during clinical trials.</p><p>In adults, symptoms of leg cramps and dizziness have been reported in patients who took more than 120 mg as a single ingestion.</p><p>In accidental overdose in children younger than 2 years of age, the maximum reported dose has been 180 mg. In children, symptoms of accidental overdose included ataxia, dizziness, vomiting, rash, diarrhea, tremor, and flushing, and elevation in alkaline phosphatase.</p><p>The highest overdose has been approximately 1.5 grams.&nbsp; No fatalities associated with overdose have been reported.</p><p>There is no specific antidote for raloxifene hydrochloride.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Selective Oestrogen Receptor Modulator, ATC code: G03XC01.</p><p><u>Mechanism of action and Pharmacodynamic effect</u></p><p>As a selective oestrogen receptor modulator (SERM), raloxifene has selective agonist or antagonist activities on tissues responsive to oestrogen. It acts as an agonist on bone and<strong> </strong>partially on cholesterol metabolism (decrease in total and LDL-cholesterol), but not in the hypothalamus or in the uterine or breast tissues.</p><p>Raloxifene&#39;s biological actions, like those of oestrogen, are mediated through high affinity binding to oestrogen receptors and regulation of gene expression. This binding results in differential expression of multiple oestrogen-regulated genes in different tissues. Data suggests that the oestrogen receptor can regulate gene expression by at least two distinct pathways which are ligand-, tissue-, and/or gene-specific.</p><p><em>a) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skeletal Effects</em></p><p>The decrease in oestrogen availability which occurs at menopause, leads to marked increases in bone resorption, bone loss and risk of fracture. Bone loss is particularly rapid for the first 10 years after menopause when the compensatory increase in bone formation is inadequate to keep up with resorptive losses. Other risk factors which may lead to the development of osteoporosis include early menopause; osteopenia (at least 1 SD below peak bone mass); thin body build; Caucasian or Asianethnic origin; and a family history of osteoporosis. Replacement therapies generally reverse theexcessive resorption of bone. In postmenopausal women with osteoporosis, Evista reduces theincidence of vertebral fractures, preserves bone mass and increases bone mineral density (BMD).</p><p>Based on these risk factors, prevention of osteoporosis with Evista is indicated for women within ten years of menopause, with BMD of the spine between 1.0 and 2.5&nbsp;SD below the mean value of a normal young population, taking into account their high lifetime risk for osteoporotic fractures. Likewise, Evista is indicated for the treatment of osteoporosis or established osteoporosis in women with BMD of the spine 2.5&nbsp;SD below the mean value of a normal young population and/or with vertebral fractures, irrespective of BMD.</p><p>i) Incidence of fractures. In a study of 7,705 postmenopausal women with a mean age of 66 years and with osteoporosis or osteoporosis with an existing fracture, Evista treatment for 3 years reduced the incidence of vertebral fractures by 47&nbsp;% (RR&nbsp;0.53, CI 0.35, 0.79; p&nbsp;&lt;&nbsp;0.001) and 31&nbsp;% (RR&nbsp;0.69, CI 0.56, 0.86; p&nbsp;&lt;&nbsp;0.001) respectively. Forty five women with osteoporosis or 15 women with osteoporosis with an existing fracture would need to be treated with Evista for 3 years to prevent one or more vertebral fractures. Evista treatment for 4 years reduced the incidence of vertebral fractures by 46 % (RR&nbsp;0.54, CI 0.38, 0.75) and 32 % (RR&nbsp;0.68, CI 0.56, 0.83) in patients with osteoporosis or osteoporosis with an existing fracture respectively. In the 4<sup>th</sup> year alone, Evista reduced the new vertebral fracture risk by 39 % (RR&nbsp;0.61, CI 0.43, 0.88). An effect on non-vertebral fractures has not been demonstrated. From the 4<sup>th</sup> to the 8<sup>th</sup> year, patients were permitted the concomitant use of bisphosphonates, calcitonin and fluorides and all patients in this study received calcium and vitamin D supplementation.</p><p>In the RUTH study<strong> </strong>overall clinical fractures were collected as a secondary endpoint<strong>. </strong>Evista reduced the incidence of clinical vertebral fractures by 35% compared with placebo (HR 0.65, CI 0.47 0.89). These results may have been confounded by baseline differences in BMD and vertebral fractures. There was no difference between treatment groups in the incidence of new nonvertebral fractures. During the whole length of the study concomitant use of other bone-active medications was permitted.</p><p>ii) Bone Mineral Density (BMD): The efficacy of Evista once daily in postmenopausal women aged up to 60 years and with or without a uterus was established over a two-year treatment period. The women were 2 to 8 years postmenopausal. Three trials included 1,764 postmenopausal women who were treated with Evista and calcium or calcium supplemented placebo. In one of these trials the women had previously undergone hysterectomy. Evista produced significant increases in bone density of hip and spine as well as total body mineral mass compared to placebo. This increase was generally a 2&nbsp;% increase in BMD compared to placebo. A similar increase in BMD was seen in the treatment population who received Evista for up to 7 years. In the prevention trials, the percentage of subjects experiencing an increase or decrease in BMD during raloxifene therapy was: for the spine 37&nbsp;% decreased and 63&nbsp;% increased; and for the total hip 29&nbsp;% decreased and 71&nbsp;% increased.</p><p>iii) Calcium kinetics. Evista and oestrogen affect bone remodelling and calcium metabolism similarly. Evista was associated with reduced bone resorption and a mean positive shift in calcium balance of 60&nbsp;mg per day, due primarily to decreased urinary calcium losses.</p><p>iv) Histomorphometry (bone quality). In a study comparing Evista with oestrogen, bone from patients treated with either medicinal product was histologically normal, with no evidence of mineralisation defects, woven bone or marrow fibrosis.</p><p>Raloxifene decreases resorption of bone; this effect on bone is manifested as reductions in the serum and urine levels of bone turnover markers, decreases in bone resorption based on radiocalcium kinetics studies, increases in BMD and decreases in the incidence of fractures.</p><p><em>b) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Effects on lipid metabolism and cardiovascular risk</em></p><p>Clinical trials showed that a 60&nbsp;mg daily dose of Evista significantly decreased total cholesterol (3 to 6&nbsp;%), and LDL cholesterol (4 to 10&nbsp;%). Women with the highest baseline cholesterol levels had the greatest decreases. HDL cholesterol and triglyceride concentrations did not change significantly. After</p><p>3 years therapy Evista decreased fibrinogen (6.71 %). In the osteoporosis treatment study,significantly fewer Evista -treated patients required initiation of hypolipidaemic therapy compared to placebo.</p><p>Evista therapy for 8 years did not significantly affect the risk of cardiovascular events in patients enrolled in the osteoporosis treatment study. Similarly, in <u>the RUTH study</u><strong>, </strong>raloxifene did not affect the incidence of myocardial infarction, hospitalized acute coronary syndrome, stroke or overall mortality, including overall cardiovascular mortality, compared to placebo (for the increase in risk of fatal stroke see section 4.4).</p><p>The relative risk of venous thromboembolic events observed during raloxifene treatment was 1.60 (CI<strong><em> </em></strong></p><p>0.95, 2.71) when compared to placebo, and was 1.0 (CI 0.3, 6.2) when compared to oestrogen or hormonal replacement therapy. The risk of a thromboembolic event was greatest in the first four months of therapy.</p><p><em>c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>Effects on the endometrium and on the pelvic floor</em></p><p>In clinical trials, Evista did not stimulate the postmenopausal uterine endometrium. Compared to placebo, raloxifene was not associated with spotting or bleeding or endometrial hyperplasia. Nearly 3,000 transvaginal ultrasound (TVUs) examinations were evaluated from 831 women in all dose groups. Raloxifene treated women consistently had an endometrial thickness which was indistinguishable from placebo. After<strong> </strong>3 years of treatment, at least a 5 mm increase in endometrial thickness, assessed with transvaginal ultrasound, was observed in 1.9&nbsp;% of the 211 women treated with raloxifene 60&nbsp;mg/day compared to 1.8&nbsp;% of the 219 women who received placebo. There were no differences between the raloxifene and placebo groups with respect to the incidence of reported uterine bleeding.</p><p>Endometrial biopsies taken after six months therapy with Evista 60&nbsp;mg daily demonstrated non-proliferative endometrium in all patients. In addition, in a study with 2.5 x the recommended daily dose of Evista there was no evidence of endometrial proliferation and no increase in uterine volume.</p><p>In the osteoporosis treatment trial, endometrial thickness was evaluated annually in a subset of the study population (1,644 patients) for 4 years. Endometrial thickness measurements in Evista treated women were not different from baseline after 4 years of therapy. There was no difference between Evista and placebo treated women in the incidences of vaginal bleeding (spotting) or vaginal discharge. Fewer Evista treated women than placebo treated women required surgical intervention for uterine prolapse. Safety information following 3 years of raloxifene treatment suggests that raloxifene treatment does not increase pelvic floor relaxation and pelvic floor surgery.</p><p>After 4 years, raloxifene did not increase the risk of endometrial or ovarian cancer. In postmenopausal women who received raloxifene treatment for 4 years, benign endometrial polyps were reported in 0.9% compared to 0.3 % in women who received placebo treatment.</p><p><em>d) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Effects on breast tissue</em></p><p>Evista does not stimulate breast tissue. Across all placebo-controlled trials, Evista was indistinguishable from placebo with regard to frequency and severity of breast symptoms (no swelling, tenderness and breast pain).</p><p>Over the 4 years of the osteoporosis treatment trial (involving 7,705 patients), Evista treatment compared to placebo reduced the risk of total breast cancer by 62 % (RR 0.38; CI 0.21, 0.69), the risk of invasive breast cancer by 71 % (RR 0.29, CI 0.13, 0.58) and the risk of invasive oestrogen receptor (ER) positive breast cancer by 79 % (RR 0.21, CI 0.07, 0.50). Evista has no effect on the risk of ER negative breast cancers. These observations support the conclusion that raloxifene has no intrinsic oestrogen agonist activity in breast tissue.</p><p><em>e) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Effects on cognitive function</em></p><p>No adverse effects on cognitive function have been seen.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption</p><p>Raloxifene is absorbed rapidly after oral administration. Approximately 60&nbsp;% of an oral dose is absorbed. Presystemic glucuronidation is extensive. Absolute bioavailability of raloxifene is 2&nbsp;%. The time to reach average maximum plasma concentration and bioavailability are functions of systemic interconversion and enterohepatic cycling of raloxifene and its glucuronide metabolites.</p><p>Distribution</p><p>Raloxifene is distributed extensively in the body. The volume of distribution is not dose dependent. Raloxifene is strongly bound to plasma proteins (98-99 %).</p><p>Biotransformation</p><p>Raloxifene undergoes extensive first pass metabolism to the glucuronide conjugates: raloxifene-4&#39;-glucuronide, raloxifene-6-glucuronide, and raloxifene-6, 4&cent;-diglucuronide. No other metabolites have been detected. Raloxifene comprises less than 1&nbsp;% of the combined concentrations of raloxifene and the glucuronide metabolites. Raloxifene levels are maintained by enterohepatic recycling, giving a plasma half-life of 27.7 hours.</p><p>Results from single oral doses of raloxifene predict multiple dose pharmacokinetics. Increasing doses of raloxifene result in slightly less than proportional increase in the area under the plasma time concentration curve (AUC).</p><p>Elimination</p><p>The majority of a dose of raloxifene and glucuronide metabolites are excreted within 5 days and are found primarily in the faeces, with less than 6&nbsp;% excreted in urine.</p><p>Special populations</p><p>Renal insufficiency - Less than 6&nbsp;% of the total dose is eliminated in urine. In a population pharmacokinetic study, a 47&nbsp;% decrease in lean body mass adjusted creatinine clearance resulted in a 17&nbsp;% decrease in raloxifene clearance and a 15&nbsp;% decrease in the clearance of raloxifene conjugates.</p><p>Hepatic insufficiency - The pharmacokinetics of a single dose of raloxifene in patients with cirrhosis and mild hepatic impairment (Child-Pugh class A) have been compared to that in healthy individuals.</p><p>Plasma raloxifene concentrations were approximately 2.5-fold higher than in controls and correlated with bilirubin concentrations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In a 2-year carcinogenicity study in rats, an increase in ovarian tumors of granulosa/theca cell origin was observed in high-dose females (279&nbsp;mg/kg/day). Systemic exposure (AUC) of raloxifene in this group was approximately 400 times that in postmenopausal women administered a 60&nbsp;mg dose. In a 21-month carcinogenicity study in mice, there was an increased incidence of testicular interstitial cell tumours and prostatic adenomas and adenocarcinomas in males given 41 or 210&nbsp;mg/kg, and prostatic leiomyoblastoma in males given 210&nbsp;mg/kg. In female mice, an increased incidence of ovarian tumours in animals given 9 to 242&nbsp;mg/kg (0.3 to 32 times the AUC in humans) included benign and malignant tumours of granulosa/theca cell origin and benign tumours of epithelial cell origin. The female rodents in these studies were treated during their reproductive lives, when their ovaries were functional and highly responsive to hormonal stimulation. In contrast to the highly responsive ovaries in this rodent model, the human ovary after menopause is relatively unresponsive to reproductive hormonal stimulation.</p><p>Raloxifene was not genotoxic in any of the extensive battery of test systems applied.</p><p>The reproductive and developmental effects observed in animals are consistent with the known pharmacological profile of raloxifene. At doses of 0.1 to 10&nbsp;mg/kg/day in female rats, raloxifene disrupted estrous cycles of female rats during treatment, but did not delay fertile matings after treatment termination and only marginally reduced litter size, increased gestation length, and altered the timing of events in neonatal development. When given during the preimplantation period, raloxifene delayed and disrupted embryo implantation resulting in prolonged gestation and reduced litter size but development of offspring to weaning was not affected. Teratology studies were conducted in rabbits and rats. In rabbits, abortion and a low rate of ventricular septal defects (&sup3;&nbsp;0.1&nbsp;mg/kg) and hydrocephaly (&sup3;&nbsp;10&nbsp;mg/kg) were seen. In rats retardation of foetal development, wavy ribs and kidney cavitation occurred (&sup3;&nbsp;1&nbsp;mg/kg).</p><p>Raloxifene is a potent antioestrogen in the rat uterus and prevented growth of oestrogen-dependent mammary tumours in rats and mice.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u>:</p><p>Povidone</p><p>Polysorbate 80</p><p>Lactose</p><p>Lactose monohydrate</p><p>Crospovidone</p><p>Magnesium stearate</p><p><u>Tablet coating</u>:</p><p>Titanium dioxide (E 171)</p><p>Polysorbate 80</p><p>Hypromellose</p><p>Macrogol 400</p><p>Carnauba wax</p><p><u>Ink</u>:</p><p>Shellac</p><p>Propylene glycol</p><p>Indigo carmine (E 132)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original package. Do not freeze. Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Evista tablets are packed either in PVC/PE/PCTFE blisters or in high density polyethylene bottles. Blister boxes contain 14, 28, or 84 tablets. Bottles contain 100 tablets.</p><p>Not all pack sizes may be marketed in all countries.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eli Lilly Nederland B.V. Papendorpseweg 83, 3528 BJ Utrecht. The Netherlands.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                18 June 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>